AJHP 70: May 15, 2013 New Approaches to Reversing Oral Anticoagulant Therapy
Expiration Date: May 15, 2016
Accreditation for Pharmacists
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity provides 2.5 hours (0.25 CEUs) of continuing pharmacy education credit (ACPE activity #0204-0000-13-442-H01-P).
Methods and Format
This activity consists of a journal supplement, an assessment (post-test), and a course evaluation. Participants must read the entire presentation, take the activity assessment, and complete the course evaluation to receive continuing education credit. A minimum score of 70% is required on the test for credit to be awarded, and participants may print their official statements of continuing education credit immediately. The estimated time to complete this activity is 2.5 hours. This activity is provided free of charge.
Target Audience
This continuing pharmacy education activity was planned to meet the needs of pharmacists in a variety of practice settings, and it would be particularly beneficial for pharmacists, clinical specialists, pharmacy managers, leaders, and educators who are interested in emerging anticoagulant therapies, thrombosis, hematology, cardiology, and patient safety.
Learning objectives
After studying these articles, the reader should be able toCompare and contrast the mechanisms of action, pharmacokinetics, and rate of bleeding complications from warfarin and target-specific oral anticoagulants.
Assess the risks for thromboembolism and bleeding in patients receiving oral anticoagulation therapy, including patients who require temporary interruption of such therapy to undergo an elective invasive procedure or surgery.
Describe the pharmacologic agents and therapeutic strategies used in patients receiving oral anticoagulant therapy who experience severe bleeding or require temporary interruption of such therapy to undergo an elective or urgent invasive procedure or surgery.
Describe the potential usefulness of coagulation assays for monitoring the effects of oral anticoagulant therapy.
Outline a plan for prompt evaluation and management of patients with or at high risk for bleeding when receiving oral anticoagulants or interrupting such therapy for an urgent invasive procedure or surgery.
Faculty
Edith A. Nutescu, Pharm.D., FCCP, Chair and Moderator
Clinical Professor
The University of Illinois at Chicago College of Pharmacy
Director, Antithrombosis Center
The University of Illinois Hospital and Health Sciences System
Chicago, Illinois
William E. Dager, Pharm.D., BCPS (AQ-Cardiology)
Pharmacist Specialist
UC Davis Medical Center
Sacramento, California
James S. Kalus, Pharm.D., BCPS (AQ-Cardiology)
Senior Manager, Patient Care Services
Department of Pharmacy Services
Henry Ford Hospital
Detroit, Michigan
Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Guidelines for Standards for Commercial Support, ASHP Advantage requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual or his or her spouse/partner has a financial relationship (e.g., employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring in the last 12 months with a commercial interest whose products or services may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on presentations.
All faculty and planners for ASHP Advantage education activities are qualified and selected by ASHP Advantage and required to disclose any relevant financial relationships with commercial interests. ASHP Advantage identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity.
The faculty and planners report the following relationships:
Edith A. Nutescu, Pharm.D., FCCP, Activity Chair
Dr. Nutescu received an honorarium for participating in the symposium and preparing this article and declared that she has served as a consultant for Daiichi-Sankyo Inc. and received a research grant and served as a consultant for Janssen Pharmaceuticals, Inc.
James S. Kalus, Pharm.D., BCPS (AQ-Cardiology)
Dr. Kalus received an honorarium for participating in the symposium and preparing this article and has declared no potential conflicts of interest.
William E. Dager, Pharm.D., BCPS (AQ-Cardiology)
Dr. Dager received an honorarium for participating in the symposium and preparing this article and has declared no potential conflicts of interest.
Susan R. Dombrowski, M.S., B.S.Pharm.
Ms. Dombrowski has declared no potential conflicts of interest.
Carla J. Brink, M.S., B.S.Pharm.
Ms. Brink has declared no potential conflicts of interest.
ASHP staff has no relevant financial relationships to disclose.
This activity is supported by an educational grant from CSL Behring.